Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model.
The use of anti-toxin human monoclonal antibodies (HMab) as treatment for C. difficile infection has been investigated in animal models and human clinical trials as an alternative to or in combination with traditional antibiotic therapy. While HMab therapy appears to be a promising option, how syste...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4210241?pdf=render |
| _version_ | 1828885460101890048 |
|---|---|
| author | Ocean R Cohen Jennifer A Steele Quanshun Zhang Diane J Schmidt Yuankai Wang Philip E S Hamel Gillian Beamer Bingling Xu Saul Tzipori |
| author_facet | Ocean R Cohen Jennifer A Steele Quanshun Zhang Diane J Schmidt Yuankai Wang Philip E S Hamel Gillian Beamer Bingling Xu Saul Tzipori |
| author_sort | Ocean R Cohen |
| collection | DOAJ |
| description | The use of anti-toxin human monoclonal antibodies (HMab) as treatment for C. difficile infection has been investigated in animal models and human clinical trials as an alternative to or in combination with traditional antibiotic therapy. While HMab therapy appears to be a promising option, how systemically administered IgG antibodies protect the colonic mucosa during Clostridium difficile infection is unknown. Using the gnotobiotic piglet model of Clostridium difficile infection, we administered a mixture of anti-TcdA and anti-TcdB HMabs systemically to piglets infected with either pathogenic or non-pathogenic C. difficile strains. The HMabs were present throughout the small and large intestinal tissue of both groups, but significant HMabs were present in the lumen of the large intestines only in the pathogenic strain-infected group. Similarly, HMabs measured in the large intestine over a period of 2-4 days following antibody administration were not significantly different over time in the gut mucosa among the groups, but concentrations in the lumen of the large intestine were again consistently higher in the pathogenic strain-infected group. These results indicate that systemically administered HMab IgG reaches the gut mucosa during the course of CDI, protecting the host against systemic intoxication, and that leakage through the damaged colon likely protects the mucosa from further damage, allowing initiation of repair and recovery. |
| first_indexed | 2024-12-13T11:26:57Z |
| format | Article |
| id | doaj.art-66b7b0782d62450a80a9609ff64fdbf8 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T11:26:57Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-66b7b0782d62450a80a9609ff64fdbf82022-12-21T23:48:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01910e11107510.1371/journal.pone.0111075Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model.Ocean R CohenJennifer A SteeleQuanshun ZhangDiane J SchmidtYuankai WangPhilip E S HamelGillian BeamerBingling XuSaul TziporiThe use of anti-toxin human monoclonal antibodies (HMab) as treatment for C. difficile infection has been investigated in animal models and human clinical trials as an alternative to or in combination with traditional antibiotic therapy. While HMab therapy appears to be a promising option, how systemically administered IgG antibodies protect the colonic mucosa during Clostridium difficile infection is unknown. Using the gnotobiotic piglet model of Clostridium difficile infection, we administered a mixture of anti-TcdA and anti-TcdB HMabs systemically to piglets infected with either pathogenic or non-pathogenic C. difficile strains. The HMabs were present throughout the small and large intestinal tissue of both groups, but significant HMabs were present in the lumen of the large intestines only in the pathogenic strain-infected group. Similarly, HMabs measured in the large intestine over a period of 2-4 days following antibody administration were not significantly different over time in the gut mucosa among the groups, but concentrations in the lumen of the large intestine were again consistently higher in the pathogenic strain-infected group. These results indicate that systemically administered HMab IgG reaches the gut mucosa during the course of CDI, protecting the host against systemic intoxication, and that leakage through the damaged colon likely protects the mucosa from further damage, allowing initiation of repair and recovery.http://europepmc.org/articles/PMC4210241?pdf=render |
| spellingShingle | Ocean R Cohen Jennifer A Steele Quanshun Zhang Diane J Schmidt Yuankai Wang Philip E S Hamel Gillian Beamer Bingling Xu Saul Tzipori Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. PLoS ONE |
| title | Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. |
| title_full | Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. |
| title_fullStr | Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. |
| title_full_unstemmed | Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. |
| title_short | Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. |
| title_sort | systemically administered igg anti toxin antibodies protect the colonic mucosa during infection with clostridium difficile in the piglet model |
| url | http://europepmc.org/articles/PMC4210241?pdf=render |
| work_keys_str_mv | AT oceanrcohen systemicallyadministerediggantitoxinantibodiesprotectthecolonicmucosaduringinfectionwithclostridiumdifficileinthepigletmodel AT jenniferasteele systemicallyadministerediggantitoxinantibodiesprotectthecolonicmucosaduringinfectionwithclostridiumdifficileinthepigletmodel AT quanshunzhang systemicallyadministerediggantitoxinantibodiesprotectthecolonicmucosaduringinfectionwithclostridiumdifficileinthepigletmodel AT dianejschmidt systemicallyadministerediggantitoxinantibodiesprotectthecolonicmucosaduringinfectionwithclostridiumdifficileinthepigletmodel AT yuankaiwang systemicallyadministerediggantitoxinantibodiesprotectthecolonicmucosaduringinfectionwithclostridiumdifficileinthepigletmodel AT philipeshamel systemicallyadministerediggantitoxinantibodiesprotectthecolonicmucosaduringinfectionwithclostridiumdifficileinthepigletmodel AT gillianbeamer systemicallyadministerediggantitoxinantibodiesprotectthecolonicmucosaduringinfectionwithclostridiumdifficileinthepigletmodel AT binglingxu systemicallyadministerediggantitoxinantibodiesprotectthecolonicmucosaduringinfectionwithclostridiumdifficileinthepigletmodel AT saultzipori systemicallyadministerediggantitoxinantibodiesprotectthecolonicmucosaduringinfectionwithclostridiumdifficileinthepigletmodel |